PHARMAC and tobacco control in New Zealand: government policy 'up in smoke'.
作者： Matire Harwood , Sarah Aldington , Richard Beasley , Shaun Holt
DOI:
关键词: Family medicine 、 Bupropion 、 Smoke 、 Medicine 、 Christian ministry 、 Disadvantaged 、 Smoking cessation 、 Tobacco control 、 Public policy 、 Limiting
摘要: There is increasing concerning amongst the medical profession in New Zealand about adverse effect that PHARMAC has on health of Zealanders through restricting availability medications. In this article, circumstances surrounding restrictions limiting smoking cessation treatment bupropion are presented. The authors conclude decision by not to fund directly contrary Government policy and inconsistent with evidence-based medicine international recommendations. It suggested seriously questions Ministry Health's commitment disadvantaged groups Zealand, particularly Maori.
参考文章(10)
S Holt, C Timu-Parata, S Ryder-Lewis, M Weatherall, R Beasley, Efficacy of bupropion in the indigenous Maori population in New Zealand. Thorax. ,vol. 60, pp. 120- 123 ,(2005) , 10.1136/THX.2004.030239
S Tonstad, C Farsang, G Klaene, K Lewis, A Manolis, AP Perruchoud, C Silagy, PI Van Spiegel, C Astbury, A Hider, R Sweet, Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. European Heart Journal. ,vol. 24, pp. 946- 955 ,(2003) , 10.1016/S0195-668X(03)00003-4
DP Tashkin, R Kanner, W Bailey, S Buist, P Anderson, MA Nides, D Gonzales, G Dozier, MK Patel, BD Jamerson, Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial The Lancet. ,vol. 357, pp. 1571- 1575 ,(2001) , 10.1016/S0140-6736(00)04724-3
Elin Roddy, Bupropion and other non-nicotine pharmacotherapies BMJ. ,vol. 328, pp. 509- 511 ,(2004) , 10.1136/BMJ.328.7438.509
ROBYN RICHMOND, NICHOLAS ZWAR, Review of bupropion for smoking cessation Drug and Alcohol Review. ,vol. 22, pp. 203- 220 ,(2003) , 10.1080/09595230100100642
Robert West, Ann McNeill, Martin Raw, Smoking cessation guidelines for health professionals: an update Thorax. ,vol. 55, pp. 987- 999 ,(2000) , 10.1136/THORAX.55.12.987
Douglas E. Jorenby, Scott J. Leischow, Mitchell A. Nides, Stephen I. Rennard, J. Andrew Johnston, Arlene R. Hughes, Stevens S. Smith, Myra L. Muramoto, David M. Daughton, Kimberli Doan, Michael C. Fiore, Timothy B. Baker, A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation The New England Journal of Medicine. ,vol. 340, pp. 685- 691 ,(1999) , 10.1056/NEJM199903043400903
Richard D Hurt, David PL Sachs, Elbert D Glover, Kenneth P Offord, J Andrew Johnston, Lowell C Dale, Moise A Khayrallah, Darrell R Schroeder, Penny N Glover, C Rollynn Sullivan, Ivana T Croghan, Pamela M Sullivan, None, A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation The New England Journal of Medicine. ,vol. 337, pp. 1195- 1202 ,(1997) , 10.1056/NEJM199710233371703
B Borman, C Mailing, N Wilson, Socio-demographic characteristics of New Zealand smokers: results from the 1996 census. The New Zealand Medical Journal. ,vol. 112, pp. 460- 463 ,(1999)
Mc Fiore, Treating Tobacco Use and Dependence Clinical Practice Guideline. ,(2000)